Elion Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Elion Therapeutics, Inc. - overview
Established
2017
Location
New York, NY, US
Primary Industry
Biotechnology
About
Founded in 2017 and based in New York, US, Elion Therapeutics, Inc. , formerly Sfunga Therapeutics operates as a biotechnology company focused on the treatment of life-threatening invasive fungal infections. In June 2024, Elion Therapeutics, Inc. raised USD 81 million in series B funding co-led by investors AMR Action Fund and Deerfield Management, with participation from Illinois Ventures.
The firm’s product line includes F001, which is a polyene antifungal designed to reduce toxicity, particularly kidney impairment in patients. Moreover, the drug SF001 provides early antifungal therapy. The company develops therapies for combating invasive fungal infections developed from cancer treatment, organ transplants, or suffering from diseases like HIV/AIDS and severe COVID-19. The company intends to use the June 2024 funding to support the development of its product.
Current Investors
Illinois Ventures, Deerfield Management, AMR Action Fund
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.eliontx.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.